Latest Manufacturing News

Page 13 of 335
Papyrus Australia says its second production-scale board run delivered significantly improved internal test results, with samples now sent to TBS for acceptance testing. The progress is tempered by a reported $365,000 cash balance, $447,000 in unused facilities and estimated funding for just 1.51 quarters.
Victor Sage
Victor Sage
30 Oct 2026
Sprintex has moved its €25.71 million Mest Water order book into commercial manufacturing after receiving A$1.3 million in customer payments. The progress comes alongside a sharply constrained funding position, with A$166,000 in cash and estimated funding of just 0.17 quarters at September-end.
Victor Sage
Victor Sage
29 Oct 2026
Yowie Group has entered FY27 with US$71,000 in cash, a 35% drop in US gross sales and a fully drawn A$4 million working capital facility. The confectionery maker is pursuing an approximately A$6 million two-tranche capital raising while its ASX quotation remains suspended.
Victor Sage
Victor Sage
29 Oct 2026
Spacetalk’s active Mobile subscriber base rose 20% to 61.4k in the September quarter, but revenue fell 32% to $3.1 million as device sales, App revenue and Schools income declined. The $10 million placement lifted cash to $5.2 million, although the company reported only 1.4 quarters of funding at its current operating cash burn.
Victor Sage
Victor Sage
29 Oct 2026
Chimeric Therapeutics has stopped enrolment and dosing in its CHM-2101 CAR-T trial after a safety review found the highest dose unsafe. With $1.35 million in cash, suspended securities and uncertain creditor negotiations, the company is now pursuing a possible recapitalisation while preserving a preclinical CDH17 pathway.
Ada Torres
Ada Torres
29 Oct 2026
Tissue Repair has increased its US Phase III chronic wound trial to approximately 112 randomised patients while shifting focus towards an April 2027 FDA 510(k) submission. The company also reported $4.74 million in cash, Australian availability of all three TR Pro+ formats and a planned $1 million share buy-back.
Ada Torres
Ada Torres
29 Oct 2026
Gowing Bros has reported a $3.49 million FY2026 net loss, with Surf Hardware International remaining deeply loss-making and shopping centre values falling by $3 million. The diversified investment group maintained a fully franked 3 cents per share final dividend as cash declined and borrowings increased.
Victor Sage
Victor Sage
29 Oct 2026
1414 Degrees has sharpened the commercial case for its Aurora precinct, signing a pathway agreement for up to 1 GW of AI data centre infrastructure and attracting potential partners for a A$350 million to A$550 million first-stage energy project. Its SiNTL battery material also showed sustained performance over more than 640 cycles, although both programs remain some distance from binding commercial revenue.
Victor Sage
Victor Sage
29 Oct 2026
Element 25 has moved its Butcherbird manganese expansion into physical execution, targeting mechanical completion in the first quarter of 2027 while pursuing a much larger battery-materials strategy. The company is also positioning a planned Louisiana HPMSM facility as a US$166 million-supported foothold in non-China supply chains, although financing and permitting remain outstanding.
Maxwell Dee
Maxwell Dee
29 Oct 2026
Firebird Metals has secured its first A$1 million ARENA payment and produced 99.999% manganese sulphate as work advances on its Perth demonstration plant. The next test is whether the company can reproduce those results with Oakover ore and move from pilot validation to customer-ready samples.
Victor Sage
Victor Sage
29 Oct 2026
IperionX has validated titanium powder capacity above 200 tonnes per annum and lifted quarterly production to 8.7 tonnes, while a new U.S. Army task order funds further manufacturing scale-up. The company ended September with US$63.0 million in cash and US$33.7 million of obligated government funding still available for reimbursement.
Victor Sage
Victor Sage
29 Oct 2026
Mesoblast has posted a 44% rise in first-quarter Ryoncil revenue to US$28 million while sharply reducing operating cash use. The biotechnology company also completed treatment in its 350-patient chronic low back pain trial and received FDA confirmation that a heart-failure BLA filing may proceed.
Ada Torres
Ada Torres
29 Oct 2026

Browse the archive

Full archive